Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Pharma & Drugs
Share your love
VSY Biotechnology to Introduce a Novel Anti-VEGF for AMD
VSY Biotechnology GmbH is proud to announce the groundbreaking development of Varliciment, a revolutionary anti-VEGF agent for the treatment of age-related macular degeneration (AMD). Varliciment distinguishes itself from existing anti-VEGF agents like brolucizumab, namely Novartis’ Beovu, by being non-generic. This…
Pantheon Receives $2.5M Funding for Corneal Implant
Pantheon Vision has secured $2.5 million in seed financing from KeraLink International (KLI), a Baltimore-based non-profit organization dedicated to eliminating corneal blindness, with a specific focus on low- and middle-income countries. This funding will launch the development bioengineered corneal implant.…
Ocular Therapeutix Gets FDA Agreement for Wet AMD Trial
Ocular Therapeutix has obtained written FDA approval for the comprehensive design of its pivotal phase 3 clinical trial, known as the SOL trial, which evaluates Axpaxli (axitinib intravitreal implant) for treating wet age-related macular degeneration (AMD) under a Special Protocol…
FDA Greenlights Phase 1 Trial for IOPCL Magnifier
OnPoint Vision has officially received FDA approval for their investigational device exemption (IDE) application, initiating the phase 1 in the pivotal clinical trial for the AccuraSee Intraocular Pseudophakic Capsular Lens (IOPCL) Magnifier (MAG). This trial focuses on the secondary implantation…
Novartis CEO Denies Ophthalmology Unit Sell-off Rumors
At the J.P. Morgan Healthcare Conference, Novartis CEO Vas Narasimhan denied rumors that the pharmaceutical giant is planning to sell its respiratory and ophthalmology units altogether. The rumors, which have been circulating for several weeks, suggested that Novartis was looking…
Novartis Initiates Sale of Ophthalmology Assets
According to sources familiar with the matter, Novartis AG is kicking off the process of selling some of its ophthalmology assets in order to prune its portfolio and concentrate on other therapeutic areas, including hematology, immunology, solid tumors, neurology, and…
Bausch + Lomb Acquires Eye Drugs from Novartis
Bausch + Lomb has announced that it will acquire the dry eye drug Xiidra (lifitegrast ophthalmic solution) 5% from Novartis. Xiidra is an eye drop without steroids that has received specific approval for treating the signs and symptoms of dry…
Tiny Eye Implant: A Diabetes Treatment Option
In Sweden, researchers have created a microscale device designed for implantation in the eye, opening up new paths for cell-based treatments for conditions like diabetes. Developed by a team from KTH Royal Institute of Technology and Karolinska Institutet, this 3D-printed…
Ocuphire and Viatris Unveil FDA Approval for Ryzumvi
Ocuphire Pharma and Viatris announced that the FDA has granted approval for Ryzumvi (phentolamine ophthalmic solution) 0.75%. This approval specifically authorizes its use in the treatment of pharmacologically-induced mydriasis, produced by adrenergic agonists (such as phenylephrine) or parasympatholytic agents (like…
Thea Pharma Introduces Glaucoma Drug Iyuzeh in the U.S.
Thea Pharma announced the launch and availability of Iyuzeh (latanoprost ophthalmic solution) 0.005% in the United States market. Iyuzeh, having obtained FDA approval in December 2022, stands as the first preservative-free latanoprost product for individuals in the US diagnosed with…